Savant Capital LLC Has $4.39 Million Stake in Bruker Corporation $BRKR

Savant Capital LLC boosted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 1,211.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 106,536 shares of the medical research company’s stock after buying an additional 98,412 shares during the period. Savant Capital LLC’s holdings in Bruker were worth $4,389,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in Bruker by 5.1% in the 1st quarter. Teacher Retirement System of Texas now owns 29,045 shares of the medical research company’s stock valued at $1,212,000 after buying an additional 1,422 shares during the last quarter. Amundi grew its holdings in shares of Bruker by 373.3% in the first quarter. Amundi now owns 42,503 shares of the medical research company’s stock valued at $1,774,000 after acquiring an additional 33,522 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Bruker by 35.6% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 40,450 shares of the medical research company’s stock valued at $1,717,000 after acquiring an additional 10,624 shares during the last quarter. Vaughan Nelson Investment Management L.P. lifted its holdings in Bruker by 71.2% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after acquiring an additional 537,845 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its position in Bruker by 60.8% in the second quarter. Public Employees Retirement System of Ohio now owns 55,672 shares of the medical research company’s stock worth $2,294,000 after purchasing an additional 21,043 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. UBS Group raised their target price on Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a research report on Tuesday. Citigroup lowered their price objective on shares of Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Barclays boosted their target price on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a research note on Tuesday, August 5th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $48.30.

Bruker Price Performance

BRKR opened at $39.93 on Friday. The firm has a 50-day moving average price of $35.02 and a 200-day moving average price of $37.08. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $64.64. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of 76.79, a PEG ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same period last year, the firm earned $0.60 EPS. Bruker’s revenue for the quarter was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Equities analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is presently -125.00%.

Insider Transactions at Bruker

In other Bruker news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.